Acorda Therapeutics, Inc.
ACOR
주식 순위
#39165
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
주가
$0.879
마지막 동기화: 2024-05-07
시가총액
$582.38K
변동 (1일)
9.88%
변동 (1년)
8,690.00%
국가
US
거래 Acorda Therapeutics, Inc. (ACOR)
카테고리
Healthcare
Acorda Therapeutics, Inc. (ACOR)의 수익
Mar 2024 기준 수익 TTM: $-304.44M
Acorda Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-304.44M입니다. 2022년에 회사는 $-35.25M의 수익을 올렸으며 이는 2021년의 수익 $-109.07M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Acorda Therapeutics, Inc.의 수익 기록 (2016 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-304.44M | 2.84% |
| 2023 | $-296.02M | 739.85% |
| 2022 | $-35.25M | -67.69% |
| 2021 | $-109.07M | 1.31% |
| 2020 | $-107.67M | -60.74% |
| 2019 | $-274.25M | -1,442.84% |
| 2018 | $20.42M | -108.11% |
| 2017 | $-251.89M | 495.92% |
| 2016 | $-42.27M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -679.61% |
IN
|
